Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
Husam Ghanim, Sanaa Abuaysheh, Jeanne Hejna, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 4, pp. e1056-e1063
Open Access | Times Cited: 154

Showing 1-25 of 154 citing articles:

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
Ralph A. DeFronzo, William Reeves, Alaa S. Awad
Nature Reviews Nephrology (2021) Vol. 17, Iss. 5, pp. 319-334
Closed Access | Times Cited: 394
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Volker Vallon, Subodh Verma
Annual Review of Physiology (2020) Vol. 83, Iss. 1, pp. 503-528
Open Access | Times Cited: 328
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Mikhail Kosiborod, Russell Esterline, Remo H.M. Furtado, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 9, pp. 586-594
Open Access | Times Cited: 211
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Alice M. Jackson, Pooja Dewan, Inder S. Anand, et al.
Circulation (2020) Vol. 142, Iss. 11, pp. 1040-1054
Open Access | Times Cited: 156
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Jorge I. Fonseca‐Correa, Ricardo Correa‐Rotter
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 153
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 149
Iron deficiency and cardiovascular disease
Gianluigi Savarese, Stephan von Haehling, Javed Butler, et al.
European Heart Journal (2022) Vol. 44, Iss. 1, pp. 14-27
Open Access | Times Cited: 120
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
Annemarie B. van der Aart‐van der Beek, Rudolf A. de Boer, Hiddo J.L. Heerspink
Nature Reviews Nephrology (2022) Vol. 18, Iss. 5, pp. 294-306
Open Access | Times Cited: 115
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Milton Packer
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 443-462
Open Access | Times Cited: 102
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Kieran F. Docherty, Paul Welsh, Subodh Verma, et al.
Circulation (2022) Vol. 146, Iss. 13, pp. 980-994
Open Access | Times Cited: 95
Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy
Shuqin Du, Hanqiang Shi, Lie Xiong, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 83
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Elaine Ku, Lucia Del Vecchio, Kai‐Uwe Eckardt, et al.
Kidney International (2023) Vol. 104, Iss. 4, pp. 655-680
Open Access | Times Cited: 72
Iron, glucose and fat metabolism and obesity: an intertwined relationship
Catriona Hilton, Rugivan Sabaratnam, Hal Drakesmith, et al.
International Journal of Obesity (2023) Vol. 47, Iss. 7, pp. 554-563
Open Access | Times Cited: 50
Advances in kidney disease: pathogenesis and therapeutic targets
Vincent Boima, Alex Baafi Agyekum, Khushali Ganatra, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access | Times Cited: 2
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, et al.
Theranostics (2021) Vol. 11, Iss. 9, pp. 4502-4515
Open Access | Times Cited: 100
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
Megumi Oshima, Brendon L. Neuen, Meg Jardine, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 11, pp. 903-914
Open Access | Times Cited: 97
Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
Niki Katsiki, Ele Ferrannini
Journal of Diabetes and its Complications (2020) Vol. 34, Iss. 12, pp. 107723-107723
Open Access | Times Cited: 78
Effect of dapagliflozin on anaemia in DAPA‐HF
Kieran F. Docherty, James P. Curtain, Inder S. Anand, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 4, pp. 617-628
Open Access | Times Cited: 74
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Jun Tang, Lifang Ye, Qiqi Yan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 59
The role of CD71+ erythroid cells in the regulation of the immune response
Tomasz M. Grzywa, Dominika Nowis, Jakub Goła̧b
Pharmacology & Therapeutics (2021) Vol. 228, pp. 107927-107927
Open Access | Times Cited: 57
Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure
Milton Packer
JACC Heart Failure (2022) Vol. 11, Iss. 1, pp. 106-114
Open Access | Times Cited: 50
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial
Camilla Fuchs Andersen, Massar Omar, Andreas Glenthøj, et al.
European Journal of Heart Failure (2022) Vol. 25, Iss. 2, pp. 226-234
Open Access | Times Cited: 48
How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure
Milton Packer
European Journal of Heart Failure (2022) Vol. 24, Iss. 12, pp. 2287-2296
Open Access | Times Cited: 47
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Yong-Ping Lu, Zeyu Zhang, Hongwei Wu, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 41
Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors
Milton Packer
European Heart Journal (2023) Vol. 44, Iss. 48, pp. 5027-5035
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top